๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation

โœ Scribed by H. ZAGHLA; R. R. SELBY; L. S. CHAN; J. A. KAHN; J. A. DONOVAN; N. JABBOUR; Y. GENYK; R. MATEO; S. GAGANDEEP; L. S. SHER; E. RAMICONE; T.-L. FONG

Book ID
108604418
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
84 KB
Volume
23
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A randomized controlled trial of late co
A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function
โœ Christopher J.E. Watson; Alexander E.S. Gimson; Graeme J. Alexander; Michael E.D ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 307 KB ๐Ÿ‘ 1 views

Renal impairment is common in patients after liver transplantation and is attributable in large part to the use of calcineurin inhibitor (CNI)-based immunosuppression. We sought to determine whether conversion to sirolimus-based immunosuppression was associated with improved renal function. In a sin

Sirolimus-based immunosuppression in liv
Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis
โœ Wenhua Liang; Dongping Wang; Xiaoting Ling; Andrew Allen Kao; Yuan Kong; Yushu S ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 786 KB

Sirolimus (SRL) is a novel immunosuppressant with antitumor properties. We performed a meta-analysis to determine whether SRL can improve patient survival and decrease the risks of tumor recurrence in patients with a pretransplant diagnosis of hepatocellular carcinoma (HCC). We searched databases fo